News articles for PAREXEL International Corporation:
Wednesday, February 8, 2012
Monday, February 6, 2012
PAREXEL to Address Innovative Approaches to Late Stage Development at Summit for Clinical Ops Executives
BOSTON, Feb. 6, 2012 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that Ramita Tandon, Global Head, Late Phase Clinical Trials and Lars-Olof Eriksson, Ph.D., MS.c., Vice President, Global Research Operations at PAREXEL will address innovative approaches to late stage development at the ...
read more Wednesday, February 1, 2012
Monday, January 30, 2012
PAREXEL Reports Second Quarter Fiscal Year 2012 Financial Results
BOSTON, Jan. 30, 2012 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL) today announced its financial results for the second quarter ended December 31, 2011.
For the three months ended December 31, 2011, PAREXEL's consolidated service revenue increased by 9.5% to $333.2 million compared with $304.4 million in the prior year period. ...
read more Monday, January 23, 2012
Wednesday, January 18, 2012
Perceptive Informatics® Medical Imaging Services Receive Top Ratings
BOSTON, Jan. 18, 2012 /PRNewswire/ -- Perceptive Informatics®, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today announced that its medical imaging services were among the top rated of its peer services in an independent survey on the medical imaging ...
read more Tuesday, January 17, 2012
Monday, January 9, 2012
Tuesday, January 3, 2012
Wednesday, December 21, 2011
Monday, December 19, 2011
Thursday, December 15, 2011
Tuesday, November 29, 2011
Wednesday, November 23, 2011
Tuesday, November 22, 2011
Monday, November 21, 2011
Tuesday, November 15, 2011
UCB and PAREXEL Sign Strategic Partnership Agreement
BOSTON, Nov. 15, 2011 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it has been selected as one of two strategic partners by UCB, a global biopharmaceutical company, to provide clinical development services worldwide. PAREXEL will work with UCB ...
read more Monday, November 7, 2011
Wednesday, November 2, 2011
Monday, October 31, 2011
PAREXEL Reports First Quarter Fiscal Year 2012 Financial Results
BOSTON, Oct. 31, 2011 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL) today announced its financial results for the first quarter ended September 30, 2011.
For the three months ended September 30, 2011, PAREXEL's consolidated service revenue increased by 6.4% to $314.7 million, compared with $295.8 million in the prior year period. ...
read more